-
Gemtuzumab ozogamicin, sold
under the
brand name Mylotarg, is an antibody-drug
conjugate (a drug-linked
monoclonal antibody) that is used to
treat acute...
-
Inotuzumab ozogamicin, sold
under the
brand name Besponsa, is an antibody-drug
conjugate medication used to
treat relapsed or
refractory B-cell precursor...
- The term
ozogamicin in the
names of
monoclonal antibodies or antibody-drug
conjugates indicates that they are
linked to a
cytotoxic agent from the class...
-
Ozogamicin:
Reintroduction Based on
Favorable Risk:Benefit Profile". ADCReview.
September 2, 2017.
Retrieved August 14, 2024. "Gemtuzumab
Ozogamicin (Mylotarg®)...
- to
their targeting properties. In 2001 Pfizer/Wyeth's drug
Gemtuzumab ozogamicin (brand name: Mylotarg) was
approved based on a
study with a surrogate...
-
expression is
known to be tied to TREM2. CD33 is the
target of
gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), an antibody-drug...
- the
differentiating promyelocytes. The
monoclonal antibody gemtuzumab ozogamicin has been used
successfully as a
treatment for APL,
although it has been...
- (AML). A
second calicheamicin-linked
monoclonal antibody,
inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate...
- for AML in the U.S.,
including venetoclax (BCL2 inhibitor),
gemtuzumab ozogamicin (CD33 antibody-drug conjugate), and
several inhibitors targeting FMS-like...
- Antibody-drug
conjugates such as
Brentuximab vedotin and
Gemtuzumab ozogamicin are
examples falling into this category.
Other less
common molecules used...
